Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Issued (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Shares Issued for 11 consecutive years, with -$250.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 36.42% to -$250.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15000.0, a 99.54% decrease, with the full-year FY2025 number at $15000.0, down 99.54% from a year prior.
  • Shares Issued was -$250.5 million for Q4 2025 at Iovance Biotherapeutics, down from $250.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $463.2 million in Q3 2023 to a low of -$463.2 million in Q4 2023.
  • A 3-year average of $334400.0 and a median of $23.8 million in 2023 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 276032.73% in 2024, then crashed 99.99% in 2025.
  • Iovance Biotherapeutics' Shares Issued stood at -$463.2 million in 2023, then increased by 14.93% to -$394.0 million in 2024, then surged by 36.42% to -$250.5 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Shares Issued are -$250.5 million (Q4 2025), $250.5 million (Q3 2025), and $15000.0 (Q1 2025).